News|Articles|March 4, 2025
Optimizing next-generation sequencing for precision oncology trials
Author(s)Thermo Fisher Scientific
This article explores how optimizing next-generation sequencing (NGS) in oncology trials can enhance patient identification, boosts efficiency, and enables diverse recruitment.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Related Content
Trending on PharmExec
1
Novo Nordisk Releases 2025 Financial Report and 2026 Sales and Operations Profit Outlook
2
Novartis’ Q4 Recap Shows Signs of Looming Patent Cliff
3
Eli Lilly Announces New $3.5 Billion Manufacturing Facility in Pennsylvania
4
FDA Rejects AstraZeneca’s Application for Subcutaneous Indication of Saphnelo
5